It is well-established that prostaglandins (PGs) affect tumorigenesis, and evidence indicates that PGs also are important for the reduced food intake and body weight loss, the anorexia-cachexia syndrome, in malignant cancer. However, the identity of the PGs and the PG producing cyclooxygenase (COX) species responsible for cancer anorexia-cachexia is unknown. Here, we addressed this issue by transplanting mice with a tumor that elicits anorexia. Meal pattern analysis revealed that the anorexia in the tumorbearing mice was due to decreased meal frequency. Treatment with a non-selective COX inhibitor attenuated the anorexia, and also tumor growth. When given at manifest anorexia, non-selective COX-inhibitors restored appetite and prevented body weight loss without affecting tumor size. Despite COX-2 induction in the cerebral blood vessels of tumor-bearing mice, a selective COX-2 inhibitor had no effect on the anorexia, whereas selective COX-1 inhibition delayed its onset. Tumor growth was associated with robust increase of PGE 2 levels in plasma -a response blocked both by non-selective COX-inhibition and by selective COX-1 inhibition, but not by COX-2 inhibition. However, there was no increase in PGE 2 -levels in the cerebrospinal fluid. Neutralization of plasma PGE 2 with specific antibodies did not ameliorate the anorexia, and genetic deletion of microsomal PGE synthase-1 (mPGES-1) affected neither anorexia nor tumor growth. Furthermore, tumor-bearing mice lacking EP 4 receptors selectively in the nervous system developed anorexia. These observations suggest that COX-enzymes, most likely COX-1, are involved in cancer-elicited anorexia and weight loss, but that these phenomena occur independently of host mPGES-1, PGE 2 and neuronal EP 4 signaling.
Introduction
Cachexia, characterized by metabolic derangements leading to weight loss, is a severe problem in several chronic diseases, particularly malignant cancer (Fearon et al., 2011; Tisdale, 2010) . Cachexia restricts the patients' tolerance and response to treatment, causes suffering and impaired quality of life, and reduces life expectancy. Cachexia differs from starvation in which weight loss induced by caloric restriction normally is followed by compensatory re-feeding mechanisms. In cancer anorexia, the expected counter-regulatory feeding response to reduced body mass is absent, indicating an uncoupling of food intake from energy expenditure (Bosaeus et al., 2001) . Indeed, the weight loss in cachexia is paradoxically associated with anorexia (persistent satiety or undesire to eat) leading to reduced food intake. Since feeding and body weight are subject to close regulation by brain homeostatic and hedonic systems, cancer-induced anorexia is likely due to a complex interplay of mediators acting on the brain, but our understanding of the pathophysiology underlying reduced appetite in cancer is incomplete. However, inflammatory signaling is a central theme in cancer anorexia (Gelin et al., 1991; Ruud et al., 2010) . In particular, inflammatory-induced prostaglandins have been proposed as key mediators (Cahlin et al., 2000b; Sandstrom et al., 1990) . Among the prostaglandins, prostaglandin E 2 (PGE 2 ) is of special interest, since inhibition or deletion of the inducible cyclooxygenase (COX-2) or the inducible terminal PGE 2 isomerase, microsomal prostaglandin E synthase-1 (mPGES-1), largely prevents the anorexia during acute inflammation (Elander et al., 2007; Lugarini et al., 2002; Pecchi et al., 2006) . Furthermore, induced synthesis of COX-2 and PGE 2 are critical in formation of many malignant tumors, foremost colorectal cancer (Brown and DuBois, 2005) . Thus, epidemiological studies have revealed that administration of traditional non-steroidal anti-inflammatory drugs, as well as selective COX-2 inhibitors, is associated with decreased incidence of colorectal cancer (Steinbach et al., 2000) , and selective inhibition of mPGES-1 with the supposedly added safety over COX and COX-2 inhibitors has emerged as an attractive approach for treating malignancies (Murakami and Kudo, 2006) .
